• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by RenovoRx Inc.

    6/27/25 4:11:01 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RNXT alert in real time by email
    S-8 1 forms-8.htm S-8

     

    As filed with the Securities and Exchange Commission on June 27, 2025

     

    Registration No. 333- 

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

    RENOVORX, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   27-1448452

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

     

    2570 West El Camino Real, Suite 320

    Mountain View, California

     

     

    94040

    (Address of Principal Executive Offices)   (Zip Code)

     

    2021 Omnibus Equity Incentive Plan

    (Full title of the plan)

     

    Shaun R. Bagai

    Chief Executive Officer

    RenovoRx, Inc.

    2570 West El Camino Real, Suite 320

    Mountain View, California 94040

    (Name and address of agent for service)

     

    (650) 284-4433

    (Telephone number, including area code, of agent for service)

     

    With a copy to:

     

    Barry I. Grossman, Esq.

    Lawrence A. Rosenbloom, Esq.

    Ellenoff Grossman & Schole LLP

    1345 Avenue of the Americas

    New York, NY 10105

    Phone: (212) 370-1300

    Fax: (212) 370-7889

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
      Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act ☐

     

     

     

     

     

     

    REGISTRATION OF ADDITIONAL SHARES
    AND INCORPORATION OF PREVIOUS REGISTRATION StatementS by reference

     

    Pursuant to General Instruction E of Form S-8, RenovoRx, Inc., a Delaware corporation (the “Registrant”), is filing this registration statement on Form S-8 (the “Registration Statement”) with the Securities and Exchange Commission (the “Commission”) to register an aggregate of 1,634,834 additional shares of common stock, par value $0.0001 per share (the “Common Stock”), available for issuance under the RenovoRx, Inc. 2021 Omnibus Equity Incentive Plan (the “2021 Plan”), including (i) 913,794 shares of Common Stock, which is equal to 2.5% of the number of shares of Common Stock outstanding on April 25, 2025 (which is the record date of the 2025 annual meeting of stockholders of the Company held on June 24, 2025 (the “2025 Annual Meeting”)), to the total number of shares of Common Stock reserved and available for issuance as awards under the 2021 Plan (with such addition to the 2021 Plan having been approved by the Company’s stockholders at the 2025 Annual Meeting) and (ii) 721,040 additional shares of Common Stock, available for issuance under the 2021 Plan, pursuant to the “evergreen” provisions of the 2021 Plan providing for an annual increase in the number of shares reserved for issuance under the 2021 Plan, which is equal to 3% of the number of shares of Common Stock outstanding on the final day of the immediately preceding calendar year.

     

    In accordance with General Instruction E of Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registrant’s prior registration statements on Form S-8 filed with the Commission on October 29, 2021 (Registration No. 333-260573), March 30, 2022 (Registration No. 333-263972), March 31, 2023 (Registration No. 333-271044), April 3, 2023 (Post Effective Amendment to Registration No. 333-271044) and April 12, 2024 (Registration No. 333-278667), except to the extent supplemented, amended or superseded by the information set forth herein. Additionally, in accordance with the instructional note to Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of Form S-8 has been omitted from this Registration Statement.

     

     

     

     

    PART II

     

    INFORMATION NOT REQUIRED IN THE PROSPECTUS

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents filed by the Registrant with the Commission pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are hereby incorporated by reference in this Registration Statement:

     

    1. The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on April 1, 2025 (the “Annual Report”);
       
    2. The Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the Commission on May 15, 2025;
       
    2. All other reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act, since the end of the fiscal year covered by the Annual Report (other than the portions of these documents not deemed to be filed); and
       
    3. The description of the Registrant’s common stock contained in the Registration Statement on Form 8-A (File No. 001-40738) filed with the Commission on August 11, 2021, including any amendment or report filed for the purpose of updating such description (including Exhibit 4.6 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Commission on March 30, 2022).

     

    All documents subsequently filed with the Commission by the Registrant pursuant to Sections 13(a), 13(c), 14, and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereunder have been sold or that deregisters all securities then remaining unsold under this Registration Statement, shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement.

     

    Any statement contained herein or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such earlier statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

     

     

     

    Item 4. Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable.

      

    Item 6. Indemnification of Directors and Officers.

     

    Section 145 of the Delaware General Corporation Law, as amended (the “DGCL”), authorizes a corporation’s board of directors to grant, and authorizes a court to award, indemnity to officers, directors, and other corporate agents, provided that the person acted in good faith and in a manner the person reasonably believed to be in the corporation’s best interests, and, with respect to any criminal action, had no reasonable cause to believe the person’s actions were unlawful. A similar standard is applicable in the case of derivative actions, except that indemnification extends only to expenses, including attorneys’ fees, incurred in connection with the defense or settlement of such action and the statute requires court approval before there can be any indemnification where the person seeking indemnification has been found liable to the corporation. The DGCL further provides that the indemnification permitted thereunder shall not be deemed exclusive of any other rights to which the directors and officers may be entitled under the corporation’s bylaws, any agreement, a vote of stockholders or otherwise.

     

    The Registrant’s Sixth Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) and Amended and Restated Bylaws (the “Bylaws”) provide for indemnification of directors and officers to the fullest extent permitted by law, including payment of expenses in advance of resolution of any such matter.

     

    Section 102(b)(7) of the DGCL permits a corporation to provide in its certificate of incorporation that a director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except (1) for any breach of the director’s duty of loyalty to the corporation or its stockholders, (2) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (3) for payments of unlawful dividends or unlawful stock repurchases or redemptions or (4) for any transaction from which the director derived an improper personal benefit. The Registrant’s Certificate of Incorporation provides that the Registrant’s directors shall not be personally liable to it or its stockholders for monetary damages for breach of fiduciary duty as a director and that if the DGCL is amended to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of the Registrant’s directors shall be eliminated or limited to the fullest extent permitted by the DGCL.

     

    Section 174 of the DGCL provides, among other things, that a director who willfully or negligently approves of an unlawful payment of dividends or an unlawful stock purchase or redemption may be held liable for such actions. A director who was either absent when the unlawful actions were approved, or dissented at the time, may avoid liability by causing his or her dissent to such actions to be entered in the books containing minutes of the meetings of the board of directors at the time such action occurred or immediately after such absent director receives notice of the unlawful acts.

     

    Further, as permitted by the DGCL, the Registrant has entered into separate indemnification agreements with each of its directors and officers that may be broader than the specific indemnification provisions contained in the DGCL. Each indemnification agreement provides, among other things, for indemnification to the fullest extent permitted by law and the Certificate of Incorporation and Bylaws against any and all expenses, judgments, fines, penalties and amounts paid in settlement of any claim. The indemnification agreements provide for the advancement or payment of all expenses to the indemnitee and for reimbursement to the Registrant if it is found that such indemnitee is not entitled to such indemnification under applicable law and the Certificate of Incorporation and Bylaws.

     

     

     

     

    The Registrant has obtained and maintains standard policies of insurance under which coverage is provided (a) to its directors and officers against loss(es) rising from claims made by reason of breach of duty or other wrongful act, and (b) to it with respect to payments that it may make to such officers and directors pursuant to the above indemnification provision or otherwise as a matter of law. The coverage provided by these policies may apply whether or not the Registrant would have the power to indemnify such person against such liability under the provisions of the DGCL.

     

    Insofar as indemnification for liabilities arising under the Securities Act of 1933, as amended (the “Securities Act”), may be permitted to directors, officers or persons controlling the Registrant under the foregoing provisions, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.

      

    Item 7. Exemption from Registration Claimed.

     

    Not applicable.

     

    Item 8. Exhibits.

     

    See the attached Exhibit Index on the page immediately preceding the signature pages hereto, which is incorporated herein by reference.

     

    Item 9. Undertakings.

     

    A. The undersigned Registrant hereby undertakes:

     

    1. To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement.

     

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

     

    Provided, however, that paragraphs (A)(1)(i) and (A)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

     

    2. That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    3. To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    B. The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    C. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

     

     

    EXHIBIT INDEX

     

    Exhibit Number   Description
    3.1   Sixth Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the Commission on August 31, 2021)
    3.2   Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 filed with the Registrant’s Current Report on Form 8-K filed with the Commission on September 11, 2023)
    4.1   Specimen Stock Certificate evidencing the Shares of Common Stock (incorporated by reference to Exhibit 4.4 to Amendment No. 4 to the Registration Statement on Form S-1 filed with the Commission on August 25, 2021)
    5.1*   Opinion of Ellenoff Grossman & Schole LLP
    10.1   Amended and Restated 2021 Omnibus Equity Incentive Plan and Forms of Stock Option Grant Notice and Option Agreement (incorporated by reference to Exhibit 10.2 filed with the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the Commission on March 30, 2022)
    23.1*   Consent of Baker Tilly US, LLP
    23.2*   Consent of Frank, Rimerman + Co. LLP
    23.3*   Consent of Ellenoff Grossman & Schole LLP (included in Exhibit 5.1)
    24.1   Power of Attorney (included on signature page)
    107   Fee filing table

     

     

    * Filed herewith

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Mountain View, State of California, on the 27th day of June, 2025.

     

      RENOVORX, INC.
         
      By: /s/ Shaun R. Bagai
        Shaun R. Bagai
        Chief Executive Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Shaun R. Bagai and Ramtin Agah, and each of them, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities (including his or her capacity as a director and/or officer of RenovoRx, Inc.) to sign any or all amendments (including post-effective amendments) to this Registration Statement on Form S-8 and any and all additional registration statements filed pursuant to Rule 462(b) of the Securities Act of 1933, as amended, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith and about the premises, as fully to all intents and purposes as they, he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or any of them, or their, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement on Form S-8 has been signed below by the following persons in the capacities and on the dates indicated.

     

    SIGNATURE   TITLE   DATE
             
    /s/ Shaun R. Bagai   Chief Executive Officer and Director   June 27, 2025
    Shaun R. Bagai   (Principal Executive Officer)    
             
    /s/ Ronald B. Kocak  

    Vice President, Controller and

    Principal Accounting Officer

      June 27, 2025
    Ronald B. Kocak   (Principal Financial and Accounting Officer)    
             
    /s/ Ramtin Agah   Director   June 27, 2025
    Ramtin Agah, M.D.        
             
    /s/ Laurence J. Marton, M.D.   Director   June 27, 2025
    Laurence J. Marton, M.D.        
             
    /s/ Una S. Ryan   Director   June 27, 2025
    Una S. Ryan, O.B.E., Ph.D., D.Sc.        
             
    /s/ Kirsten Angela Macfarlane   Director   June 27, 2025
    Kirsten Angela Macfarlane        
             
    /s/ Robert J. Spiegel   Director   June 27, 2025
    Robert J. Spiegel, M.D., FACP        

     

     

     

    Get the next $RNXT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $RNXT

    DatePrice TargetRatingAnalyst
    11/1/2021$16.00Buy
    Roth Capital
    10/6/2021$15.00Buy
    Maxim Group
    More analyst ratings

    $RNXT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Agah Ramtin bought $29,400 worth of shares (21,000 units at $1.40), increasing direct ownership by 3% to 734,460 units (SEC Form 4)

      4 - RenovoRx, Inc. (0001574094) (Issuer)

      6/9/25 6:03:27 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Agah Ramtin bought $13,500 worth of shares (15,000 units at $0.90), increasing direct ownership by 1% to 1,113,460 units (SEC Form 4)

      4 - RenovoRx, Inc. (0001574094) (Issuer)

      4/17/25 6:10:32 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Bagai Shaun bought $6,821 worth of shares (7,500 units at $0.91), increasing direct ownership by 2% to 320,040 units (SEC Form 4)

      4 - RenovoRx, Inc. (0001574094) (Issuer)

      4/16/25 6:08:22 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RNXT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights

      Q1 2025 RenovoCath® Revenues of ~$200,000, Exceeding Expectations and Anticipated to Continue Growing Sequentially with New Customer Purchase Orders and Reorders Cash on Hand of $14.6 Million Anticipated to Fully Fund both RenovoCath Commercialization Scale-up and Continued Progress Towards the Completion of the Ongoing Phase III TIGeR-PaC Clinical Trial Completion of the TIGeR-PaC Clinical Trial Enrollment and Review of Second Interim Analysis by Data Monitoring Committee on Target for 2025 Company to Host Conference Call at 4:30 p.m. ET RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializ

      5/15/25 4:05:00 PM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st

      RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath©, a novel, FDA-cleared drug-delivery device, today announced that Chief Executive Officer, Shaun Bagai, will participate in a fireside chat at the Alliance Global Partners (A.G.P.) Virtual Healthcare Company Showcase hosted by Scott Henry, Managing Director and Healthcare Analyst at A.G.P., on May 21, 2025. Mr. Bagai will share recent business developments, highlighting continuing momentum with the Company's RenovoCath commercialization, as well as progress in the ongoing Phase III TIGeR-PaC clinical trial. TIGeR-PaC is evaluat

      5/14/25 8:30:00 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform

      Patent Expands Protection of TAMP therapy platform, Including Methods to Deliver an Agent, such as a Chemotherapeutic Drug, Near a Tumor RenovoRx Currently Holds a Strong and Growing IP Portfolio with 19 Issued Patents and 12 Pending Patents Supporting the Commercialization of RenovoCath Device RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced that it has received an Issue Notification from the U.S. Patent and Trademark Office (USPTO) indicating that U.S. patent NO. 12,290,564, becomes effective today, May 6, 2025.

      5/6/25 8:30:00 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RNXT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Executive Officer Bagai Shaun

      4 - RenovoRx, Inc. (0001574094) (Issuer)

      7/3/25 4:45:33 PM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Agah Ramtin

      4 - RenovoRx, Inc. (0001574094) (Issuer)

      7/3/25 4:45:34 PM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Clinical Officer Gentry Leesa

      4 - RenovoRx, Inc. (0001574094) (Issuer)

      7/3/25 4:45:31 PM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RNXT
    SEC Filings

    See more
    • SEC Form S-8 filed by RenovoRx Inc.

      S-8 - RenovoRx, Inc. (0001574094) (Filer)

      6/27/25 4:11:01 PM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RenovoRx Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - RenovoRx, Inc. (0001574094) (Filer)

      6/25/25 5:17:08 PM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by RenovoRx Inc.

      10-Q - RenovoRx, Inc. (0001574094) (Filer)

      5/15/25 4:15:48 PM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RNXT
    Leadership Updates

    Live Leadership Updates

    See more
    • RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships

      LOS ALTOS, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced today that Ryan Witt has joined the Company in the new role as Senior Vice President, Head of Corporate Strategy and Partnerships. Mr. Witt's appointment highlights RenovoRx's commitment to explore and execute on clinical and commercial business development opportunities not only for its RenovoGem™ investigational combination product (currently in Phase III clinical development), but also opportunities with the Company's foundational FDA

      6/10/24 8:30:00 AM ET
      $IMMX
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RenovoRx Closes $6.1 Million Private Placement

      With Material Participation From Insiders, Offering Proceeds to Help Drive Company Towards Second Interim Analysis of the Pivotal TIGeR-PaC Phase III Clinical Trial by Late 2024 RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that it has closed a private placement (the "private placement" or the "financing") resulting in gross proceeds of approximately $6.1 million, before deducting offering expenses. The closing of this private placement extends RenovoRx's cash runway as RenovoRx continues its ongoing pivotal TIGeR-PaC Phase III c

      1/29/24 8:30:00 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D.

      RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced the appointment of Michel Ducreux, M.D., Ph.D. to the Company's Scientific Advisory Board (SAB). Dr. Ducreux is the Head of the Gastrointestinal Oncology Unit and Gastrointestinal Oncology Tumor Board at Gustave Roussy, Professor of Oncology at Paris-Saclay University in France, and Vice-Chair of ESMO GI. Dr. Ducreux was trained in medicine, gastroenterology, and gastrointestinal tract oncology at the University of Paris Sud. Dr. Ducreux earned his master's degree in biological sciences and PhD in health sciences. He has held pre

      11/16/23 8:35:00 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RNXT
    Financials

    Live finance-specific insights

    See more
    • RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights

      Q1 2025 RenovoCath® Revenues of ~$200,000, Exceeding Expectations and Anticipated to Continue Growing Sequentially with New Customer Purchase Orders and Reorders Cash on Hand of $14.6 Million Anticipated to Fully Fund both RenovoCath Commercialization Scale-up and Continued Progress Towards the Completion of the Ongoing Phase III TIGeR-PaC Clinical Trial Completion of the TIGeR-PaC Clinical Trial Enrollment and Review of Second Interim Analysis by Data Monitoring Committee on Target for 2025 Company to Host Conference Call at 4:30 p.m. ET RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializ

      5/15/25 4:05:00 PM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET

      RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, today announced it will host its first quarter 2025 financial results conference call on May 15th, 2025, at 4:30 p.m. ET. Additional details will be available in the Investor Relations section of the Company's website at https://ir.renovorx.com/. Event: RenovoRx First Quarter 2025 Financial Results Conference Call Date: Thursday, May 15, 2025 Time: 4:30 p.m. ET Live Call: 1-877-407-4018 (U.S. Toll Free) or 1-201-689-8471 (International) Webcast:

      5/1/25 8:30:00 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RNXT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Roth Capital initiated coverage on RenovoRx with a new price target

      Roth Capital initiated coverage of RenovoRx with a rating of Buy and set a new price target of $16.00

      11/1/21 11:49:10 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maxim Group initiated coverage on RenovoRx with a new price target

      Maxim Group initiated coverage of RenovoRx with a rating of Buy and set a new price target of $15.00

      10/6/21 8:24:28 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RNXT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by RenovoRx Inc. (Amendment)

      SC 13G/A - RenovoRx, Inc. (0001574094) (Subject)

      2/14/23 4:51:34 PM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by RenovoRx Inc.

      SC 13G - RenovoRx, Inc. (0001574094) (Subject)

      4/14/22 2:24:24 PM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by RenovoRx Inc.

      SC 13G - RenovoRx, Inc. (0001574094) (Subject)

      2/14/22 6:33:04 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care